Edgewise Therapeutics Shares Tumble on Underwritten Public Offering Pricing

Dow Jones

04-02

By Denny Jacob

Edgewise Therapeutics shares tumbled 29% in premarket trading on Wednesday after pricing its underwritten public offering of 9.9 million shares of its common stock.

Shares were trading around $17.98. The stock is up 8.8% over the last year.

The muscle disease biopharmaceutical company's offering price for its public offer is $20.13 a share, which it expects will bring in gross proceeds of $200 million before expenses.

The offer is expected to occur on Thursday. Edgewise intends to use the net proceeds from the offering to support the potential U.S. launch of sevasemten in patients with Becker muscular dystrophy, if approved, among other efforts.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

April 02, 2025 08:07 ET (12:07 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2524671694"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2524671694\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2524671694?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-02 20:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2524671694","market":"sg","top_or_hot":-1,"title":"Edgewise Therapeutics Shares Tumble on Underwritten Public Offering Pricing","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Edgewise <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares tumbled 29% in premarket trading on Wednesday after pricing its underwritten public offering of 9.9 million shares of its common stock. \n</p>\n<p>\n  Shares were trading around $17.98. The stock is up 8.8% over the last year. \n</p>\n<p>\n  The muscle disease biopharmaceutical company's offering price for its public offer is $20.13 a share, which it expects will bring in gross proceeds of $200 million before expenses. \n</p>\n<p>\n  The offer is expected to occur on Thursday. Edgewise intends to use the net proceeds from the offering to support the potential U.S. launch of sevasemten in patients with Becker muscular dystrophy, if approved, among other efforts. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 02, 2025 08:07 ET (12:07 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Edgewise Therapeutics Shares Tumble on Underwritten Public Offering Pricing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEdgewise Therapeutics Shares Tumble on Underwritten Public Offering Pricing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-04-02 20:07</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Edgewise <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares tumbled 29% in premarket trading on Wednesday after pricing its underwritten public offering of 9.9 million shares of its common stock. \n</p>\n<p>\n  Shares were trading around $17.98. The stock is up 8.8% over the last year. \n</p>\n<p>\n  The muscle disease biopharmaceutical company's offering price for its public offer is $20.13 a share, which it expects will bring in gross proceeds of $200 million before expenses. \n</p>\n<p>\n  The offer is expected to occur on Thursday. Edgewise intends to use the net proceeds from the offering to support the potential U.S. launch of sevasemten in patients with Becker muscular dystrophy, if approved, among other efforts. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 02, 2025 08:07 ET (12:07 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2524671694","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2524671694","pubTimestamp":1743595620,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Edgewise Therapeutics shares tumbled 29% in premarket trading on Wednesday after pricing its underwritten public offering of 9.9 million shares of its common stock.Shares were trading around $17.98. The stock is up 8.8% over the last year.The muscle disease biopharmaceutical company's offering price for its public offer is $20.13 a share, which it expects will bring in gross proceeds of $200 million before expenses.The offer is expected to occur on Thursday. Edgewise intends to use the net proceeds from the offering to support the potential U.S. launch of sevasemten in patients with Becker muscular dystrophy, if approved, among other efforts.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4539":"次新股","BK4007":"制药","LENZ":"Therapeutics","EWTX":"Edgewise Therapeutics, Inc."},"translate_title":"Edgewise Therapeutics股价因承销公开发行定价而暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EWTX":1,"LENZ":1},"content_text":"By Denny Jacob \n\n\n \n\n\n  Edgewise Therapeutics shares tumbled 29% in premarket trading on Wednesday after pricing its underwritten public offering of 9.9 million shares of its common stock. \n\n\n  Shares were trading around $17.98. The stock is up 8.8% over the last year. \n\n\n  The muscle disease biopharmaceutical company's offering price for its public offer is $20.13 a share, which it expects will bring in gross proceeds of $200 million before expenses. \n\n\n  The offer is expected to occur on Thursday. Edgewise intends to use the net proceeds from the offering to support the potential U.S. launch of sevasemten in patients with Becker muscular dystrophy, if approved, among other efforts. \n\n\n \n\n\n  Write to Denny Jacob at denny.jacob@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 02, 2025 08:07 ET (12:07 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}